FAS and neoplasm: Moreover, after immunotherapy, activated immune cells and cytokines enhance the sensitivity of tumor cells to chemotherapy, making tumor cells more sensitive to the killing effects mediated by T cells through the Fas/Fas‐1 and granzyne B pathways.